SciClone Pharmaceuticals (SCLN) Narrows 3Q Loss
SciClone Pharmaceuticals (NASDAQ:SCLN - News) shares climbed 13% after the company narrowed its third-quarter loss to $1.31 million, or 3 cents a share, from $3.09 million, or 7 cents a share, with revenue from its lead product, Zadaxin, up 18% to $8.27 million. Contract revenue slipped to $26,000 from $134,000 last year. It's expecting a slight profit for 2006 and revenue above $32 million for the year, as fourth-quarter product revenue should rise compared to the third quarter. It's holding onto cash guidance of $38 million by the end of the year.
posted by Stock Administrator @ 10:41 PM
0 Comments:
Post a Comment
<< Home